# Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

> **NCT04810091** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 79 (actual)

## Conditions studied

- Locally Advanced Neuroendocrine Neoplasm
- Metastatic Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Placebo Administration
- **OTHER:** Questionnaire Administration
- **DRUG:** Telotristat Ethyl

## Key facts

- **NCT ID:** NCT04810091
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-18
- **Primary completion:** 2025-08-31
- **Final completion:** 2026-08-03
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810091, "Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04810091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*